The global capsule endoscopy market size is expected to reach USD 880.51 million by 2033, registering a CAGR of 8.06% from 2026 to 2033, according to a new report by Grand View Research, Inc. The rising prevalence of colorectal cancer, gastrointestinal diseases, and other intestinal disorders is one of the major factors supporting market growth. In addition, the growing demand for accurate, faster, and precise diagnostic tools coupled with favorable government initiatives are some of the other factors boosting the market growth.
Based on the product, the wireless capsule segment dominated the market in 2023 and is anticipated to register a significant growth rate over the forecast period. It is attributed to the rising utilization rates of capsule endoscopes for the screening of the esophagus, colon, and small intestine in recent years. In addition, the introduction of technologically advanced wireless capsules along with the presence of affirmative reimbursement policies are likely to drive the growth of the segment in the coming years.
Capsule endoscopes are further divided into the type of small bowel, esophageal, and colon. In 2020, the small bowel endoscopy capsules segment held the largest revenue share of 72.3%. This share is attributable to the benefits provided by these devices in the diagnosis and treatment of diseases such as inflammatory bowel disease, Obscure GI Tract Bleeding (OGIB), Crohn’s disease, and small bowel neoplastic lesions. In addition, the growing prevalence of these conditions that would require the utilization of small bowel capsules for diagnosis is anticipated to support market growth during the forecast period.
Based on application, in 2024, the OGIB segment accounted for the largest revenue share of 45.4% in the market owing to the advantages provided by this endoscopy in the detection of obscure GI tract bleeding, such as real-time visualization of the small intestine and precise and faster diagnosis. In addition, shifting preference toward capsule-based endoscopic screening as compared to traditional screening for OGIB is yet another prominent factor boosting the market growth.
In 2024, based on end-use, the hospitals segment accounted for the largest revenue share of 55.3%. It is due to the rising adoption and utilization of capsule endoscopes and endoscopy systems in hospitals. In addition, supportive reimbursement policies provided by healthcare institutions as well as the government is further boosting the market growth. Furthermore, since hospitals are the primary healthcare facilities that are opted by patients in many countries across the globe, the number of surgical procedures performed in hospitals is higher and this signifies higher growth potential.
North America dominated the market and accounted for the largest revenue share of 43.6% in 2024. This high share is attributable to factors, such as increasing adoption of technologically advanced capsule-based endoscopy products and systems, rising preference for minimally invasive surgeries, and better-quality healthcare systems and infrastructures. Furthermore, the growing prevalence of chronic conditions, such as gastrointestinal disorders, OGIB, and cancer, are other factors boosting the market growth.
The pandemic of COVID-19 has significantly impacted the market majorly due to the rescheduling, postponement, or cancellation of elective surgeries. In addition, supply chain disruptions and changes in the regulatory scenario for curbing the infection caused due to the COVID-19 virus are other factors that have hindered the market growth during the COVID-19 pandemic. Furthermore, the training of medical professionals for capsule endoscopy was restricted due to the pandemic. According to a 2021 article published in BMJ Journals, some of the institutions have undertaken e-learning modules for capsule endoscopy training due to pandemic situations and are planning to move to traditional training patterns post-pandemic.
Request a free sample copy or view report summary: Capsule Endoscopy Market Report
The small bowel capsule endoscopy segment led the market with the largest revenue share of 54.67% in 2025
The OGIB (obscure GI tract bleeding) segment led the market with the largest revenue share of 45.30% in 2025. The technological advancements and development of artificial intelligence algorithms for image analysis, with companies working on AI-assisted platforms to streamline the interpretation of capsule endoscopy results, are anticipated to drive market growth.
The hospitals segment led the market with the largest revenue share of 55.52% in 2025 and is expected to grow at the fastest CAGR during the forecast period.
North America dominated the global capsule endoscopy market with the largest revenue share of 43.55% in 2025. The high prevalence of several diseases, such as Gastrointestinal (GI) disorders, which include Crohn's disease, gastrointestinal bleeding, celiac disease
Grand View Research has segmented the global capsule endoscopy market report based on type, application, end use, and region:
Capsule Endoscopy Type Outlook (Unit Volume, In Thousand Units; Revenue, USD Million, 2021 - 2033)
Small Bowel Capsule Endoscopy
Esophageal Capsule Endoscopy
Colon Capsule Endoscopy
Others
Capsule Endoscopy Application Outlook (Unit Volume, In Thousand Units; Revenue, USD Million, 2021 - 2033)
OGIB (obscure GI tract bleeding)
Crohn’s disease
Small Intestine tumor
Others (Celiac, NSAID reactions)
Capsule Endoscopy End Use Outlook (Unit Volume, In Thousand Units; Revenue, USD Million, 2021 - 2033)
Hospitals
Outpatient Facilities
Capsule Endoscopy Regional Outlook (Revenue, USD Million) (Unit Volume, In Thousand Units) 2021 - 2033
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Capsule Endoscopy Market
CapsoVision
Shangxian Minimal Invasive Inc.
INTROMEDIC
Medtronic
Olympus
AnX Robotics
JINSHAN Science & Technology (Group) Co., Ltd.
Check-Cap
RF Co., Ltd.
BioCam
"The quality of research they have done for us has been excellent..."